REJECTION
CONTINUES TO BE A MAJOR PROBLEM confronting the transplant recipient and his surgeon. Acute reject,ion of renal allografts is commonly treated by increasing the daily oral dose of corticosteraids. Multiple complications of this therapy, including gastrointestinal hemorrhage and increased susceptibility to infection, have been reported. Intermittent large-dose intravenous corticosteroid therapy has the theoretical, but still unproved, potential of halting rejection while avoiding the toxicity associated with frequent oral administration. Intravenous corticosteroid therapy has been used by some clinicians to treat rejection [2, 41. However, many clinical transplant teams have not been convinced of the advantages of the i&rave-nous route and have continued to treat relettion by increasing the oral dose of corticosteroids to 200-300 mg./day usually given in divided doses. A recent toxicologic study demonstrated that an even larger intravenous dose of methylprednisolone sodium succinate, than has been used to treat rejection previously, is well tolerated by humans [9] . Our study deals with the use of very large intravenous doses of methylprcdnisolonc, that is 30 mg./kg., for treating allograft rejection in dogs and humans. In addition, the circulating half-life of methylprednisolone using a highly specific gas chromatographic method was defined for the first time [l] . The notable absence of serious side effects, probably related to the relatively short circulating half-life of this drug when administered intravenously, and the ability of this dosage regimen to modify allograft rejection are documented in this study.
MATE'RIALS AND METHODS
Fourteen beagles underwent bilateral recipient nephrectomy and received renal allografts. Urine was collected in metabolic cages. Serial hematologic, coagulation, and blood and urine studies were obtained. Endogenous creatinine, inulin, and para-aminohippurate (PAH) clearances were determined. Serial biopsies were taken of the kidney allograft, spleen, mesenteric lymph nodes, and liver. Sections of these tissues were examined using hematoxylin-eosin and methyl green pyronin stains [7] . All studies were not obtained in every dog. Serial renal arteriograms were performed before and after rejection in four dogs. No technical problems or other operative complications were cncountercd. All kidneys functioned promptly and serum creatinine was less than 1.2 mg./lOO ml. 24 hours after transplantation in all animals. Subsequent elevation of serum creatinine to 2.0 mg./lOO ml. or higher was interpreted as reflecting the onset of acute reject#ion. Each dog was then treated with an intravenous "pulse" of methylprednisolone, 30 mg.,/kg., administered in 500 ml. of 5% dextrose in 0.2% NaCl over 1 hour. To substantiate the diagnosis of reject.ion an open renal biopsy was performed just prior to administering the pulse in 10 dogs. Frequent serum levels of met,hylprednisolone were determined using gas chromatography as described by Bacon during the 24 hours after administration of the pulse [l] . Serial studies were continued until death at, which time an autopsy was performed upon all dogs. One additional dog with a renal allograft was treated with four consecutive daily pulses of methylprednisolone 30 mg./kg. In this dog open renal biopsies were taken at the time of transplantation, immediately prior to each pulse and at autopsy.
Similar serial blood and urine studies were obtained in six control dogs. Four dogs were used to study t,hc toxicology of intravenous mcthylprednisolone; two dogs received 15 mg./kg., and two received 30 mg./kg. Two other dogs served as untreated controls; that is, they underwent bilateral recipient, nephrectomy, received renal allografts, and were studicd serislly, but. were not t.rcated for rejection with methylprednieolone.
A seventh dog also .served as an untreated control. This animal underwent' bilat,eral reripient nephrectomy, received a renal allograft, and underwent serial Olin renal biopsies at, the same times after transplantation as the dog treated with four ronsecutives pulses. Rejection in this dog, however, wa,s not treated wit'h methylprednisolone.
The records of 100 consecutive recipients of human renal allotransplants performed at the University of Michigan Medical Center between ,June 18, 1969 and Oct. 20, 1971 were reriewcd and acute rejection episodes were identified.
These episodes were defined as those occasions when an abrupt deterioration in renal function occurred in the absence of other possible explanations such as technical or infectious complications. Often other signs of rejection were present. These rejection episodes were treated with single or multiple pulses of intravenous met'hylprednisolone 30 mg.,/kg. given in 200 ml. of 5% dextrose in water over one-half hour. A pulse was repeated every 48-72 hours for a maximum of three or four doses as needed to reverse rejection. In most cases, the daily oral maint'enance dose of prednisone was also raised slightly, t,hat is, t'he maintenance dose was increased by 25% or 10 mg., whichever was larger.
RESULTS

Animal Studies
Elevation of serum creatinine to 2.0 mg./lOO ml. or higher, reflecting the onset of acute rejection, occurred 6.2 * 0.7 days after transplantation. The mean survival of dogs treated with a single pulse was 9.6 I+ 0.3 days. This did not differ significantly when compared with untreated control dogs. No clinical evidence of t,oxicity from the pulse, such as gaetrointestinal bleeding, was observed in an> dog.
Hemntologic, Coagulation, Blood, and Urine Chemistry Studies x'o significant changes or biochemical evidence of toxicity consequent to methylprednisolone pulse therapy were demonstrated in serial studies of hematocrit, white blood cell count, relative and absolute lymphocyt,e counts ; platelet count; prot.hrombin t.ime ; partial thromboplastin time; thrombin clotting time ; quantitative fibrinogen levels ; serum creatinine; blood urea nitrogen; serum sodium, potassium, chloride, carbon dioxide, and magnesium; bilirubin; serum glutamic oxalacetic transaminaae ; total serum protein and albumin; or urine sodium, potassium, chloride and magnesium. The changes in blood studies observed in dogs treated with a pulse while undergoing rejection were similar to changes observed in untreated animals during rejection. Thr only changes observed in the four dogs not operated upon which received either 15 or 30 mg.,'kg. methylprednisolone intravenously was a rise in total n-hit? blood cell count and ;I marked reduction in absolute lymphocyte count.
Renal Clearance Studies and Renal Arteriograms
In six dogs endogenous creatinine clearance and in three dogs inulin and PAH clearance studies were obtained before and after pulse therapy. Creatinine clearance decreased precipitously in most dogs between the day prior to pulse therapy and the day of pulse administration confirming that the rejection process was very active at this time (Table 1) . Pulse therapy seemed to halt this trend as indicated by modest improvements in creatinine clearance in three of six dogs, inulin clearance in all three dogs studied, and PAH clearance in two of three dogs (Tables 2 and 3 ). The serial renal arteriograms obtained during rejection showed the typical progressive changes of rejection. No improvement was demonstrated in the arteriographic appearance of rejection subsequent to pulse therapy.
Serum LDH
Serum LDH levels were elevated at the time of therapy for rejection (Table 4) . LDH was reduced in five of nine dogs treated with intravenous methylprednisolone and the mean LDH level of the entire group of nine dogs treated with pulse was also reduced. These changes in LDH did not reach statistical significance in this small group of animals.
Total Urine LDH, Urine Volume, and Osmolality
Total urine LDH was also elevated at the time of therapy for rejection (Table 4) . Total urine LDH excretion was reduced in six of six dogs within 48 hours after administration of methylprednisolone.
Twenty-four-hour urine volume was increased in all eight dogs within 48 hours after pulse therapy. The mean increase was 692 ml,, and the least increase observed was 490 ml.; in five dogs the magnitude of the increase exceeded the 500-ml. volume of fluid administered intravenously as a vehicle for methylprednisolone.
Urine osmolality dropped t,o a low level at t'he time of rejection, and in four dogs the urine osmolality increased within 48 hours after a single pulse. The standard deviations of these determinations were large and the numbers of animals relat'irely small; none of these changes in urine LDH, urine volume, or osmolality reached statistical significance.
Histology
Histologic evidence of rejection was present in the allografts of all 10 dogs biopsied immediately prior to "pulse" therapy. A striking reduction in the cellular infiltrate was noted in 2 of 10 dogs biopsied 48 hours subsequent to "pulse" therapy (Figs. 1, 2, and 3 ). Both pyroninophilic and nonpyroninophilic cells were reduced. In biopsies taken at a later time the rejection process again progressed. In the other eight dogs biopsied after receiving a pulse no convincing improvement in the histology of rejection could be consistently substantiated in the multiple sections examined. Rejection proceeded relentlessly in the allografts of the two dogs which served as untreated controls; t#liere was a progressive accumulation of pyroninophilic and nonpyroninophilic cellular infiltrate, necrosis of tubules and vessels, thrombosis of vessels, and multiple hemorrhagic infarcts.
In the dog receiving four pulses at 24-hour intervals beginning on the fifth day after transplantation, a delayed but more sustained reduction of the cellular infiltrate in the renal allograft occurred. Significant reversal of the histologic pattern of rejection was first noted 24 hours after the third pulse. The dog died 24 hours after receiving the fourth pulse; this was 9 days after transplantation. The serum creatinine had remained below 1.0 mg./lOO ml. even in the sample drawn just shortly prior to deat'h. A kidney biopsy t'aken at autopsy exhibited relatively mild focal infiltrates of mononuclear cells. The cause of death was not apparent, but a wound infection was present.
Biopsies of spleen, mesenteric lymph nodes, and liver were taken in 10 dogs at the time of renal transplantation, time of pulse treatment, 48 hours subsequent to pulse, and at autopsy. These organs remained histologica,lly normal.
Methylprednkolone
Circulating Half-life Serial serum levels of methylprednisolone were measured in 13 dogs during the 24 hours after administration of a pulse. A high mean peak blood level of 1415 k 679 pg/lOO ml. was reached immediately after administration of the pulse (Table 5 ). The mean circulating half-life was 3.48 + 0.70 hours. The very high mean correlation coefficient of -0.93 -t 0.06 when serial levels were correlated with time suggests that methylprednisolone is metabolied by a first-order reaction (Fig. 4) .
Autopsies
Gross evidence of rejection was obvious in all renal allografts at autopsy. The grafts were swollen, edematous, and hemorrhagic; areas of necrosis within the renal parenchyma were present and frequently the renal vessels were thrombosed. In several dogs purulent exudate was present at the renal biopsy sites. A special effort was made to identify possible toxic manifestations of steroid pulse therapy but none ivere found. In no dogs was gastrointestinal bleeding, gastric or intestinal ulcerations, or pulmonary infections demonstrated.
Humnn Experience
Xnety-eight episodes of acute rejection were identified in 100 consecutive renal allotransplant recipienk. In 90 of these episodes, or 92% of the time, the rejection process ~vas either-halted or reversed with pulse t,herspy. Most of the patients received more than one pulse, but on several occasions rejection n~s promptly reversed with a single pulse. No complications occurred which could be attributed to bliis therapy.
Discussion
The most common method used to treat acute rejection of renal allografts is to temporarily increase the dose of corticosteroids. antilymphocyte globulin, arc probably less effective and have been used only as adjuncts. Unfortunately, current methods to reverse rejection are not always successful and the use of high doses of corticosteroids is frequently associated with significant complications. Indeed, it, has been common for recipients of renal allografts to die from complications secondary to immunosuppressive therapy, even though rejection is controlled [ll] .
The use of large intravenous doses of corticosteroids for reversing rejection has several potential advantages. A maximal circulating concentration of the drug can be achieved promptly. If the intravenous dose is administered intermittently, that is every 2 or 3 days, many of the toxic side effects of corticosteroids might be avoided. This would be especially true if it could be proved that the half-life of the particular corticosteroid utilized was relatively short. Considerable clinical evidence exists from experience gained in the treatment of other diseases that intermittent administration of corticosteroids, that is every second or third day, is associated with fewer side effects while therapeutic effectiveness is maintained [8, lo] . Despite these potential advantages the quest,ion of the effectiveness of such a regimen for reversing rejection has not been verified. Only a few transplant teams have reported experi-JOURNAL OF SURGICAL RESEARCH, VOL.
12, NO. 3, MARCH 1972 ence with intermittent pulse therapy to treat reject,ion, and little experimental evidence is available [2, 41. The half-life of methylprednisolone in dogs was demonstrated to be relatively short, that is, 31% hours, and a high maximum concentrat'ion was immediately achieved. The gas chromatographic method used to determine serum levels of methylprednisolone is specific and reproducible [l] . Coburg et ~2. demonstrated that the half-life of prednisolone is also relatively short in dogs [4] . However, they utilized the Porter-Silber chromagen technique which is less specific than gas chromatography. Collins et al. demonstrated that after oral administration of prednisolone the peak serum level is usually not reached for l-2 hours, and the peak level is frequently only one-half the level reached with I-V administration of an equivalent dose [5] .
When used alone there is little evidence that corticosteroids are able to consistently prevent rejection in dogs. Zukosky et al. were able to prolong survival of canine renal allografts by administering 30 mg. of prednisone per day [12] . On the basis of most investigators' experience the administration of a single dose of corticosteroids might not be expected to have much influence on the rejection process. However, we felt that if rejection could be modified using a single dose of corticosteroids, this would be the most easily interpretible evidence that pulse therapy might be effective. A variation in response was expected because of the antigenic disparity between donor and recipient in an outbred population of dogs, and the impossibility of consistently identifying the same stage of rejection for administering pulse therapy to different animals. The reductions in serum and urine LDH and increases in urine volume and osmolality observed in most dogs, and the reduction in cellular infiltrates seen histologically in two dogs are good biologic evidence that a single pulse does modify rejection. These changes occurred despite the fact that rejection was quite advanced at the time of pulse therapy in our experimental animals. There was no evidence of a spontaneous tendency for rejection to reverse in untreated animals in t'his study and in other experiments in our laboratory.
The dog treated with four consecutive pulses is especially interesting to us, but since only a single experiment of this type was performed, additional studies are needed for confirmation. A reduction in cellular infiltrate was not seen until 8 days after transplantation, and after the dog had received three pulses. This suggests that more than one pulse would be required to more consitently demonstrate a histologic reduction in cellular infiltrate. The absence of side-effects in this and the ot'her dogs in the experiment that received methylprednisolone intravenously is somewhat surprising since this species is known to be quite sensitive to the toxic effects of corticosteroids. This lack of side effects is probably related to the short half-life of methylprednisolone.
Kountz et al. as these investigators to treat rejection and have not added any adjunctive therapy. In our clinical experience rejection was reversed more than 90% of the time with single or multiple pulses as required. No significant side effects occurred. A comparative study would be required to determine the ideal dose of intravenous corticosteroids to reverse rejection.
Summary
Intravenous administration of large doses of methylprednisolone sodium succinate was demonstrated to modify rejection in both canine and human renal allografts. One dose of intravenous methylprednisolone 30 mg./kg. administered during acute rejection in dogs resulted in an increase in urine volume and osmolality, and a decrease in serum and urine LDH. In two dogs treated with a single dose and in one dog treated with four consecutive daily doses histologic evidence of reversal of rejection with reduction of cellular infiltrate was achieved. Ninety-two percent of rejections encountered in 100 consecutive human recipi-FEDUSKA ET AL.: METHYLPREDNISOLONE "PULSE" THERAPY "15 enta of renal allografts were halted or reversed with intravenous methylprednisolone 30 mg./ kg. given every 48-72 hours to a maximum of three or four doses. No significant side effects were observed either in dogs or humans with this therapy. The mean circulating half-life of intravenous methylprednisolone was determined to be 3.48 * 0.7 hours in dogs. Intermittent intravenous administration of methylpretlnisolone has the potential advantage of being associated wit,11 fewer side effects than frequent oral administration and has been Aown to be an effective method for modifying rei ec tion.
